Denosumab Produces Promising Results Against Giant Cell Tumor of the Bone In a Phase II clinical trial, 86% of patients with giant cell tumor of the bone responded to treatment with the investigational targeted therapy denosumab. These results were presented at the 2009 annual meeting of the American... Continue Reading

According to a recent article published in the Journal of Pediatric Surgery, the surgical removal of cancer spread to the lung significantly improves survival among pediatric patients diagnosed with osteosarcoma. Osteosarcoma is a cancer that starts in the bone. It is a disease that mainly affects young... Continue Reading

According to a recent article published in the Journal of Pediatric Surgery, computed tomograhy (CT) scans miss over one-third of cancers that have spread to the lung in pediatric patients diagnosed with osteosarcoma. Osteosarcoma is a cancer that starts in the bone. It is a disease that mainly affects... Continue Reading

Among patients with high-risk Ewing’s sarcoma family of tumors (ESFT), treatment with an intensified chemotherapy regimen of ifosfamide, carboplatin, and etoposide (ICE) plus cyclophosphamide, doxorubicin, and vincristine (CAV) resulted in good control of disease and made it easier to perform surgery.... Continue Reading

According to results published in the Annals of Oncology, childhood cancer survivors with bone cancer who were treated with Adriamycin® (doxorubicin) demonstrated declining heart function at 22 years following treatment. Adriamycin is a commonly used chemotherapy agent for the treatment of several types... Continue Reading

According to the results of a study published in the Journal of the National Cancer Institute, osteosarcoma patients treated with the chemotherapy drugs cisplatin and doxorubicin every two weeks did not have better survival than patients who received the same drugs every three weeks. Osteosarcoma is... Continue Reading